Background: Frequent attenders in medical settings account for a disproportionate amount of health-care resources. Little is known about service use and costs of secondary care in those frequent attenders presenting with medically unexplained symptoms.
Aims: To compare health-care use and costs of patients with medically unexplained symptoms with other frequent attenders in secondary care.
Method: In a sample of 400 frequent attenders of secondary care services, those presenting with medically unexplained symptoms were identified by a review of medical records. Their use of health-care resources was compared with that of other frequent attenders.
Results: Of the frequent attenders 17% had at least two medically unexplained consultation episodes. These patients had a greater number of referrals to secondary care and were more likely to undergo particular investigations.
Conclusions: Frequent attenders with medically unexplained symptoms account for levels of service use and expenditure that are comparable with other frequent attenders, but the use and cost of medical investigations in this group are significantly greater.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1192/bjp.180.3.248 | DOI Listing |
J Pain
January 2025
Innovation, IMPlementation And Clinical Translation (IIMPACT) in Health, University of South Australia, Kaurna Country, Adelaide, Australia.
Group-delivered programs for chronic pain are evidence-based and frequently used. The contribution of group factors to outcomes is unclear and there are no integrated findings on consumer perceptions of the group itself in programs for people with chronic pain. The aim of this systematic review was to search and synthesise qualitative data specifically related to the group itself in studies investigating group-delivered programs for people with chronic pain (PROSPERO, CRD42023382447).
View Article and Find Full Text PDFBackground: Belzutifan, a first-in-class HIF-2α inhibitor, has shown antitumour activity as monotherapy and in combination with cabozantinib in patients with previously treated advanced kidney cancer. The phase 2 LITESPARK-003 study was designed to determine the antitumour activity and safety of belzutifan in combination with cabozantinib in patients with advanced clear-cell renal cell carcinoma that was previously untreated (cohort 1) or previously treated with immunotherapy (cohort 2). Here, we report results from cohort 1 of this clinical trial.
View Article and Find Full Text PDFOtolaryngol Head Neck Surg
January 2025
Department of Head and Neck Surgery, Kaiser Permanente Oakland Medical Center, Oakland, California, USA.
Objective: To quantify the otolaryngologic diagnoses encountered in outpatient clinics by otolaryngology-head and neck surgery (OHNS) residents during their 5 years of postgraduate training.
Methods: This is a retrospective review at a single institution following 5 consecutive graduating resident cohorts throughout their training. The electronic health record was queried for OHNS clinic encounters from 2013 through 2022 during which the resident physicians were included as the visit provider or assistant to an attending physician.
Trans R Soc Trop Med Hyg
January 2025
School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki 852-8102, Japan.
Background: Little is known about snakebites by Naja samarensis, a species unique to the Philippines. The aim here is to describe the clinical and epidemiological characteristics of patients bitten by this medically important cobra in the Eastern Visayas.
Methods: A hospital-based prospective study analysed the features of snakebite patients attending Eastern Visayas Medical Center between June 2022 and May 2023.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!